Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3786 results
Bayer's Nexavar gets Health Canada approval for differentiated thyroid cancer
Bayer is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Drug Research > Drug Discovery & Development > News
Celladon announces new clinical development initiatives for MYDICAR
Celladon Corporation has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Drug Research > Drug Discovery & Development > News
Debiopharm, Nobelex to develop new antibiotics for N. Gonorrhoeae and Enteric Species
By PBR Staff Writer
Swiss biopharmaceutical firm Debiopharm and Canada-based CAnaNobelex Biotech have entered into collaboration for two discovery programs for the development of new antibiotics targeting Neisseria gonorrhoeae and enteric species using a new mechanism of action.
Drug Research > Drug Discovery & Development > News
Morphotek, Sorrento to develop morphotek antibody drug conjugates
By PBR Staff Writer
Concortis Biosystems, a subsidiary of Sorrento Therapeutics, has announced a collaboration to develop new antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology.
Drug Research > Drug Discovery & Development > News
Orexo reports top-line data from Phase III trial of Zubsolv to treat opioid dependence
Orexo has announced top-line data from a Phase 3 clinical trial demonstrating that Zubsolv (buprenorphine/naloxone CIII sublingual tablet) is as effective as Suboxone film in the treatment of opioid dependence.
Drug Research > Drug Discovery & Development > News
Mersana, EMD Serono to develop new antibody-drug conjugates
By PBR Staff Writer
US-based Mersana Therapeutics has entered into an agreement with Merck's biopharmaceutical division EMD Serono, to jointly develop next-generation antibody-drug conjugates (ADCs).
Drug Research > Drug Discovery & Development > News
TG Therapeutics, Ligand ink licensing deal to develop inhibitors of IRAK4
By PBR Staff Writer
US-based clinical-stage biopharmaceutical firm TG Therapeutics has entered into an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitor research program.
Drug Research > Drug Discovery & Development > News
BIND, Roche partner to discovery new nanomedicines
By PBR Staff Writer
BIND Therapeutics, a US-based clinical-stage nanomedicine platform company, has entered into a research agreement with Roche to discover new nanomedicines using Accurins to treat diseases in therapeutic areas outside of oncology.
Drug Research > Drug Discovery & Development > News
Merrimack Pharmaceuticals to regain worldwide rights to develop and commercialize MM-121
Merrimack Pharmaceuticals has reached an agreement with Sanofi to regain worldwide rights to develop and commercialize MM-121, a monoclonal antibody designed to block ErbB3 (HER3) activation in patients with heregulin-positive tumors and improve response to standard of care treatments.
Drug Research > Drug Discovery & Development > News
Navitor Pharmaceuticals announces $23.5m Series A financing
Navitor Pharmaceuticals, a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, has announced a $23.5m Series A financing.
Drug Research > Drug Discovery & Development > News
Pfizer, Cellectis enter into cancer immunotherapy collaboration
By PBR Staff Writer
Pfizer has entered into a global strategic collaboration with France-based Cellectis to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.
Drug Research > Drug Discovery & Development > News
DNAtrix's DNX-2401 drug receives FDA fast track status
By PBR Staff Writer
The U.S. Food and Drug Administration (FDA) has granted Fast Track status to DNAtrix's drug DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma.
Drug Research > Drug Discovery & Development > News
Critical Outcome Technologies receives orphan drug designation for COTI-2
Critical Outcome Technologies has announced that the US Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, Lilly announce resubmission of new drug application to FDA for empagliflozin
Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company have announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the US Food and Drug Administration (FDA).
Drug Research > Drug Discovery & Development > News
TG Therapeutics releases preliminary clinical results from Phase II study of TG-1101
TG Therapeutics has announced preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA(TM)), the oral BTK inhibitor from Pharmacyclics/Janssen.
Drug Research > Drug Discovery & Development > News
91-105 of 3786 results